Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Safety and Effectiveness of the Yaari Extractor for Management of Shoulder Dystocia

NCT05913609 · tracked via the Priya Life Science USA tracker
Sponsor
FetalEase Ltd
Phase
Not applicable
Started
2023-11-15
Last updated
2025-11-25

Condition(s) studied

Shoulder Dystocia

Investigational drug(s) / intervention(s)

Yaari Extractor

Yaari Extractor: The Yaari Extractor device is a single-use prescription device for neonatal extraction in deliveries that are complicated by shoulder dystocia. The Study Device consists of two curved, rigid plastic-coated metal Arms with Handles which are used for control of the device outside the body, and an elastic Engagement Element which conforms to the maternal and neonatal anatomy, and which is used for direct contact with the entrapped neonate within the birth canal.

Study summary

Prospective, multi-center, single arm with historical control, to verify the safety and effectiveness of the Yaari Extractor used by board certified or board eligible U.S. OB/GYN physicians in the management of shoulder dystocia.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Subject 18 years of age or older at time of consent. 2. Subject planning on vaginal birth. 3. Singleton pregnancy in vertex presentation. 4. Full-term pregnancy having completed 37 weeks or more gestational weeks. 5. Able and willing to provide written informed consent prior to enrollment. 6. In the opinion of the Investigator, the subject has sufficient mental capacity to understand the informed consent form (ICF). 7. Subject with fetus experiencing shoulder dystocia as defined by ACOG Practice Bulletin 178 "Shoulder dystocia is most commonly diagnosed as failure to deliver the fetal shoulder(s) with gentle downward traction on the fetal head, requiring additional maneuvers to effect delivery." Exclusion Criteria: 1. Patients who have undergone attempted delivery using ancillary standard of care maneuvers, to include first-line maneuvers (McRoberts ± suprapubic pressure with downward traction on the fetal head), prior to use of the Yaari Extractor. (NOTE: Hyperflexion of the hips or legs is allowed prior to and during use of the Yaari Extractor.) 2. Cesarean section is planned for the patient. 3. Obstetric contraindications to vaginal birth. 4. Subject carrying fetus with known significant chromosomal or structural anomalies. 5. Clinically estimated fetal weight ≥5kg in non-diabetic subjects. 6. Clinically estimated fetal weight ≥4.5kg in subjects with diabetes. 7. Subject has any general health condition or systemic disease that may represent, in the opinion of the Investigator, a potential increased risk associated with device use or pregnancy. 8. Bleeding disorders, such as thrombocytopenia, von Willebrand's disease, bleeding disorder currently using anticoagulation medication, etc. 9. Any maternal disease or disorder that precludes the subject from pushing effectively. 10. If the maternal cervix is not fully dilated. 11. If the fetal head is not completely out of the birth canal. 12. In the presence of a non-reducible nuchal cord.

Primary outcome measure(s)

  • Number of successful neonate deliveries with the Yaari Extractor device — immediately after the intervention
    First Primary Effectiveness Endpoint
  • Time interval (minutes) from the diagnosis of the shoulder dystocia until the neonate's delivery — immediately after the intervention
    Second Primary Effectiveness Endpoint
  • Maternal and neonatal adverse events — through study completion, an average of 5 days
    Primary Safety Endpoint

Trial sites (4)

FacilityCityRegionStatus
University of Miami - Jackson Memorial Miami Florida Recruiting
Rosemark WomenCare Specialist Idaho Falls Idaho Recruiting
Unified Women's Clinical Research Winston-Salem North Carolina Recruiting
Inova Fairfax Medical Campus Falls Church Virginia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05913609 on ClinicalTrials.gov ↗ ← All trials in the USA